Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2014
Q3
Sell
-1,900
Closed -$19K 10510
2014
Q2
$19K Sell
1,900
-1,700
-47% -$14.4K ﹤0.01% 8148
2014
Q1
$46K Sell
3,600
-244,100
-99% -$3.62M ﹤0.01% 6954
2013
Q4
$3.71M Buy
247,700
+211,800
+590% +$2.72M ﹤0.01% 2163
2013
Q3
$396K Sell
35,900
-23,000
-39% -$192K ﹤0.01% 4410
2013
Q2
$468K Buy
+58,900
New +$375K ﹤0.01% 4167

Other funds holding HALO

UBS's HALO Position: Q3 2014 in Review

UBS increased its Halozyme (HALO) stake by 346% in Q3 2014, buying an estimated $988K and bringing the position to 133,766 shares worth $1.22M. The position accounts for ﹤0.01% of the portfolio, ranked #3397.

UBS first reported a position in HALO in Q2 2013 and has held it in 6 quarters since. 121 funds tracked by Wall St. Rank hold HALO as of Q3 2014.

  • UBS held 133,766 shares of Halozyme worth $1.22M as of Q3 2014.
  • UBS bought 103,746 Halozyme shares in Q3 2014, an estimated $988K.
  • Halozyme made up ﹤0.01% of UBS's portfolio in Q3 2014, its #3397 holding.
  • UBS first reported a position in Halozyme in Q2 2013 and has held it in 6 quarters since.
  • 121 funds tracked by Wall St. Rank held Halozyme as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.